Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab + Nivolumab in advanced hepatocellular carcinoma after TKI failure
NCT04567615Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 17
01
Overview
A Phase 2 trial of relatlimab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Feb 2021; status: completed.
02
Drugs
relatlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04567615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567615.